Entospletinib Dimesylate

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameEntospletinib Dimesylate
Drug Alias NameEntospletinib恩托替尼ENTOEntospletinibumGS-9973 (free base)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitors
TargetsSpleen tyrosine kinase
Therapy Area/IndicationsRichter's SyndromeGraft vs Host DiseaseAnemia +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIgnota Labs LtdGilead Sciences IncKronos Bio Inc
Active IndicationsN/A
Inactive IndicationsRichter's SyndromeGraft vs Host DiseaseAnemia +[19] 

Other Information

ATC CodeN/A
Related LinksN/A